Conditions: Cystic Fibrosis
Keywords: Prescription drugs Administration, oral Durable medical equipment Kinetics
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 21
Healthy volunteers: no

Brief summary:
Study Hypothesis: Pioglitazone may decrease inflammation in cystic fibrosis lung disease.

Primary outcomes: Markers of inflammation (neutrophils, elastase, cytokines and bacteria)will be measured in induced sputum specimens before and after a 4 week treatment period with pioglitazone in clinically stable CF patients.

Detailed description:
* Single-center, open label study of pioglitazone in clinically stable patients with mild to moderate CF lung disease
* Induced sputum will be obtained from each subject at enrollment (Baseline) and again following 28 days of pioglitazone treatment (End of Treatment)
* Changes in markers of inflammation in the sputum samples will be assessed
* Safety measures, including complete blood count (CBC), serum chemistry, Erythrocyte sedimentation rate (ESR), C-Reactive Protein (CRP), urinalysis and spirometry, will also be assessed

Arms:
arm 1: All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily Other names: Actos, Takeda

Interventions: intervention 1: pioglitazone
Intervention descriptions: intervention 1: All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.

Protocol document: